MedPage Today on MSN
Bubbles of Prostate Cancer Info; Cancer Drug Tops Moneymakers; Small Kidney Tumors
News, features, and commentary about cancer-related issues ...
Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Graham Heron from Dorset urges UK men to get PSA tests for early prostate cancer detection, credits Dorchester Hospital and ...
Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...
In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.
In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...
Stockhead on MSN
Health check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results